Competencies

• Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
• Management team very experienced in celltherapeutics production and clinical development with a strong scientific background
• Integration of key competencies and expertise in a lean core structure enabling a fast development
• Vivendy has an excellent scientific position since the inventor and core researcher for MPS IVA is integrated in the teams decisions

Management Team

Executive Director
Dr.Gosse Bruinsma

(Communication; Business Development; Corporate Management; Project Controlling)

• Dr. Bruinsma has more than 20 years experience in the biotechnology and pharmaceutical industries. Dr. Bruinsma most recently served as Executive Chairman of Curidium Medica plc, an AIM-listed company in London and prior to that as Director, President and CEO of Axonyx Inc. a publically traded company in New York until he successfully merged the company with a private USA-based company in October 2006. He was also President of Axonyx Europe BV between October 2000 and October 2006.
• In addition, he was European Medical Director for Zambon, Milan; VP for Medical and Regulatory Affairs for ClinTrials Research, UK; Medical Director for Forest Laboratories in New York; General Manager and VP Development for Chrysalis Clinical Services Europe, Switzerland and VP Development for Crucell BV Leiden Netherlands.
• Dr. Bruinsma received his undergraduate degree from McGill University, Montreal and his medical degree from the University of Leiden, The Netherlands. He currently also serves as Director on the Supervisory Board of Agendia BV based in Amsterdam as well as non-executive Director with Curidium Medica plc, London.

Director Clinical and Regulatory Affairs
Dr. Gertrud Thormann-Huber

• Master of Pharmacy and PhD in Natural Sciences specialized in pharmaceutical biology
• Over 30 years experience in all fields of drug development with special emphasis on regulatory affairs with FDA and EMEA, the leading Health Authorities worldwide
• Specialized in the development and registration of NCEs, mainly bio-tech compounds
• Track record of successful approvals of many submitted NDAs including three Roche blockbusters (Rocephin®, Roferon® (Interferon) and Neupogen®)
• As independent consultant for the past 11 years advised and assisted several companies in the development and regulatory strategies for successful approval of their ERT products in LSDs

Medical Director
Professor Dr. Arndt Rolfs

• Degree in Medicine at the Universities of Mainz and Vienna and habilitation
• Active clinician in the international field of neuroscience since more than 20 years
• Internationally renowned in the field of diagnosis and treatment of hereditary diseases
• Principal investigator in and responsible for the design of several clinical studies in the area of rare diseases (e.g. sifap-project; world largest study in young stroke patients; www.sifap.eu)
• Reviewer for the EMEA and FDA in several programs, esp. in the field of treatment of rare diseases
• Founder and co-founder of biotech companies

Technical Director
Dr. Hans Paul Walliser

(Cell line, Enzyme Production & Purification)

• Diploma and PhD in Chemistry from the University of Basel, Switzerland
• Over 26 years of experience in the Biotech industry
• Many years in different management positions at Novartis Switzerland including biopharmaceutical development, planning and support, biotechnology development and production, and downstream processing
• Several years of managing and consulting experience ans Managing Director of LSMW, Switzerland, a company providing Total Life Science Solutions and Senior Consultant Biotechnology and Director for Biopharma Management Services at GE Healthcare Bio-Sciences
• Co-founder and co-organizer of the "Interlaken Conference on Advances in Production of Biologics" and the "Singapore Biologics Manufacturing Conference"

CFO
Dr. Florian Fischer

(Finance controlling)

• Dr. Fischer is founder and CEO of MedVenture Partners – a Munich based corporate finance and strategy advisory company focusing on the life sciences and healthcare.
• He has been serving as (part-time, interim) CFO to a number of growth companies and has acted as lead advisor in a variety of transactions and financings in the life sciences and health care.
• Prior to founding MedVenture Partners Dr. Fischer worked with KPMG for more than 6 years, responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG.
• Dr. Fischer holds a graduate degree in business administration and a PhD in public health and is an active lecturer at the Odeon Center for Entrepreneurship of the Ludwig-Maximilian-Universität Munich.

Board of Directors

Chairman of the Board of Directors

• Dr. Gerhard Ries; General Partner, BioMedInvest AG, Basel; Switzerland

 

Members of the Board of Directors

• Dr. Annegret de Baey-Diepolder; Partner, TVM Capital, Munich; Germany
• Dr. Jörg Neerman; Partner, LSP, Life Sciences Partners; Munich; Germany
• Dr. Domenico Valerio; Partner; AESCAP Venture Management BV, Amsterdam, Netherlands
• Prof. Dr. Walter Dettling; Chairman of the Board of Directors Inotech Biotechnologies Ltd., Basel, Switzerland

Investors

About Aescap Venture Management

Aescap Venture Management BV, is a venture capital firm focusing on the creation and growth of European (bio)medical companies. Through early and active involvement in the companies, Aescap Venture will achieve an accelerated development of its portfolio companies and their products. Aescap Venture currently has € 103 M under management. From its first fund, Aescap Venture invested in eight biomedical companies and led six investment rounds. The company was founded by Michiel de Haan, founder and former managing partner of Atlas Venture and Dr Dinko Valerio, founder and former CEO of Crucell, a Euronext/NASDAQ-listed biotechnology company. Other partners are Patrick Krol, an entrepreneur and expert in life science marketing and business development, and Kreske Nickelsen, a previous director of life sciences at 3i. For more information please visit: www.aescap.com

About BioMedInvest AG

BioMedInvest is a leading independent European venture capital firm, providing private equity and mezzanine financing to early- to mid-stage healthcare and life-science companies. Since 2003, BioMedInvest has invested in more than 20 highly innovative enterprises four of which have already successfully completed their IPO (Arpida AG, Santhera Pharmaceuticals AG) or have been acquired by leading companies in the industry (GlycArt Biotechnology AG) or by strategic investors (Thommen Medical AG). With more than CHF 210 million in capital under management and a strong team of experienced specialists with broad expertise and extensive scientific and financial networks, BioMedInvest has established itself as one of the leading early-stage healthcare investors in Europe. For additional information please visit: www.biomedvc.com

About LSP Life Sciences Partners

LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors. Further information on Life Science Partners is available at www.lspvc.com

About TVM Capital

The TVM Capital Life Science Practice is one of the largest investors in venture and growth deals in biotechnology and pharmaceuticals in Europe, with a strong presence and a substantial team in the US and a growing presence in Asia through our network of venture partners and advisors. The Life Science team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and almost 40 IPOs from our biotechnology and pharmaceutical portfolio of companies. 20 years of track record of successful investing and value creation in traditional early and late-stage venture as well as venture growth and growth capital make the TVM Capital Life Science Practice a unique partner for the needs of the pharmaceutical industry. For more information please visit: www.tvm-capital.com

Location

Vivendy Therapeutics Ltd.
Peter Merian-Str. 45
CH-4052 Basel
Switzerland

Tel: +41-61-271 87 80
Fax: +41-61-271 87 81
web: www.vivendy.ch
mail: info[at]vivendy.ch